We are seeking a Senior Manager, FP&A to join our Boston-based Finance team. Reporting to the Director, FP&A, this individual will support and own planning, forecasting, and analytics across a significant portion of the Company's operating expense base, partnering directly with department leaders to translate strategic priorities into credible financial plans.
This is a broad, high-visibility role with exposure to both our scientific organization and our corporate functions. You will be a core contributor to the annual planning cycle, quarterly reforecasts, monthly close, cash and runway analysis, and Board-level reporting. The scope is intentionally wide — we are looking for someone who wants to understand how the whole company works, not just one slice of it.
ResponsibilitiesOperating plan and forecasting: Own the annual operating plan, quarterly reforecasts and long-range plan for assigned areas.
Driver-based modeling: Build and maintain driver-based models for headcount, personnel costs, external spend, consumables, capital and allocations.
Variance analysis and reporting: Prepare monthly and quarterly reporting packages with budget-versus-actual variance analysis. Include forward-looking commentary on the full-year outlook.
Cash and runway modeling: Contribute to cash forecasting, burn analysis and runway management. Support financing planning, Board materials, budget presentations and external operating expense guidance.
Contract and investment modeling: Build financial models and decision support for CRO/CDMO and vendor contracts, collaborations, capital equipment, software and facilities. Evaluate resource allocation trade-offs across programs, platforms and infrastructure.
Headcount and compensation modeling: Model headcount plans, compensation cycles, recruiting plans and payroll/benefits forecasts with People Experience & Operations.
Month-end close and expense accounting: Work with Accounting on accruals, reclasses and spend validation. Check that expense classification follows policy and external reporting requirements.
Systems, controls and process: Improve FP&A processes, reporting templates and self-service reporting in NetSuite and planning tools. Support internal controls, SOX-readiness and audit requests on budgeting and forecasting.
QualificationsEducation: Bachelor's degree in Finance, Accounting, Economics or a related quantitative field.
Experience: 7–10+ years of progressive FP&A, corporate finance or accounting experience.
Budget and forecast ownership: Demonstrated ownership of multiple full budget and forecast cycles for meaningful cost centers, including direct work with senior non-finance leaders.
Modeling: Advanced Excel and financial modeling skills, able to build a clean, auditable, flexible model from a blank sheet.
Accounting: Strong command of accrual accounting and the month-end close process.
Preferred biotech and systems background: Biotech, pharma or life sciences experience, ideally at a clinical-stage company, with exposure to R&D cost centers. Also hands-on NetSuite and an EPM/planning tool (e.g., Adaptive), plus familiarity with public company reporting (10-Q/10-K, SOX, Board reporting).
Skills Required
- Bachelor's degree in Finance, Accounting, Economics, or a related quantitative field
- 7-10+ years of progressive FP&A, corporate finance, or accounting experience
- Ownership of multiple full budget and forecast cycles for meaningful cost centers
- Experience partnering directly with senior non-finance leaders
- Advanced Excel and financial modeling skills, including building auditable models from a blank sheet
- Strong command of accrual accounting and month-end close processes
- Biotech, pharma, or life sciences experience, ideally in a clinical-stage company
- Exposure to research and development cost centers
- Hands-on NetSuite experience
- Experience with an EPM or planning tool such as Adaptive
- Familiarity with public company reporting, including 10-Q, 10-K, SOX, and Board reporting
What We Do
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader medicines for serious diseases, including oncology, autoimmune, inflammatory, cardiovascular, and cardiometabolic conditions. Its QuEEN platform combines proprietary molecular glue libraries with proteomics, structural biology, computational chemistry, and AI/machine learning to discover and develop treatments aimed at disease-driving proteins and pathways long considered undruggable across multiple therapeutic areas.









